A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chihuahua, Mexico, CP31205
- Unidad de Investigación en Salud
-
San Luis Potosí, Mexico, CP 78240
- Hospital Ignacio Morones Prieto SLP
-
-
Federal District
-
Mexico City, Federal District, Mexico, CP54055
- Clinical Research Institute
-
Mexico City, Federal District, Mexico
- Hospital Central Militar
-
México City, Federal District, Mexico, CP 06726
- Hospital General de Mexico
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, CP45190
- Instituto Dermatólogico de Jalisco "Dr. Jose Barba Rubio"
-
Zapopan, Jalisco, Mexico, CP45200
- Hospital Dr. Ángel Leaño
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, CP64000
- MIRC/OCA Hospital
-
Monterrey, Nuevo León, Mexico, CP64460
- Centro de Dermatologia de Monterrey
-
Monterrey, Nuevo León, Mexico, CP64460
- Hospital Universitario "José E. González"
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of onychomycosis of the target toenail
- A positive fungal culture from the target toenail
Exclusion Criteria:
- Any disease or condition that might cause nail abnormalities or may interfere with clinical evaluations
- Presence of tinea pedis (athletes foot)
- Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
Topical application once a day for 9 months
|
|
Experimental: 2
|
Topical application once a day for 9 months
|
|
Experimental: 3
|
Topical application once a day for 9 months
|
|
Placebo Comparator: 4
|
Topical application once a day for 9 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in area of infected nail
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in mycological results
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DPSI-IDP-108-P2-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.